You have no items in your shopping cart.
Diabetes Research
As the prevalence of diabetes continues to rise, sustainable treatment options are a critical necessity. The transplantation of stem cell-derived beta cells presents a novel and long-term solution for those suffering from type-I diabetes. A method to derive functional insulin-producing beta cells from hPSCs designed by Pagliuca, et al. (2014) presents a six-stage protocol using a combination of multiple small molecules and growth factors (including CHIR99021, Retinoic Acid, SANT-1, LDN193189, Compound E, and RepSox) and has shown promise in ameliorating hyperglycemia in mice.
-
CHIR99021
Highly potent inhibitor of GSK3α and GSK3β. Learn More$125.00 -
Y27632 (2HCl)
Highly potent inhibitor of p160-Rho-associated coiled protein kinase (ROCK), 10 mg Learn More$125.00 -
LDN193189 (HCl)
BMP inhibitor in tetrahydrochloride form, 10 mg Learn More$125.00 -
RepSox
Potent and selective inhibitor of the TGF-β type 1 receptor, 10 mg Learn More$125.00 -
Retinoic Acid
Acts as a ligand for nuclear retinoic acid receptors (RARs, specifically RARα/β/γ), 500 mg Learn More$75.00 -
Thiazovivin
Potent and selective inhibitor of Rho kinase (ROCK) activity, 10 mg Learn More$150.00 -
Triiodothyronine Salt
Analog of thyroid hormone that selectively binds to and activates β1 thyroid hormone receptor (TRβ1), 500 mg Learn More$150.00